Last October Novo Nordisk announced that it had ... formulation to be as effective as injectable insulin – and says a future advance in drug delivery could still make it a reality.

The US Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic ... persons with type 2 diabetes. It is designed as an injectable solution for subcutaneous delivery.

The alliance has focused on the addition of Mallya to Novo Nordisk’s FlexTouch pen injector for insulin delivery ... as well as working towards complete systems that layer in glucose monitoring ...

Despite this, the company remains a leader in diabetes care, with Ozempic and Wegovy commanding a 55% market share in the growing weight-loss drug sector. On the positive side, Novo Nordisk also ...

For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide ... as well as death due to cardiovascular disease. Type 2 diabetes (T2D) patients with CKD will ...